A longtime surgical podiatrist, global key opinion leader on the diabetic lower limb, practicing diabetic foot salvage surgeon, active researcher, published author, and principal/national investigator on over 60+ randomized controlled trials and post-market surveillance studies for the biotechnology and pharmaceutical industry. He has instituted and led inpatient diabetic foot salvage surgery service lines, as well as hospital based outpatient centers for wound healing.

Dr. Cazzell has served on medical advisory boards internationally, is an active consultant and global product strategist, emerging markets, division of plastic and reconstructive surgical services of a large not for profit tissue procurement and advanced biologic human cell and tissue organization. He is a global product consultant for advanced biologics and regenerative medicine technology corporations.

Dr. Cazzell is the founder and Medical Director of Limb Preservation Platform (LPP), a clinical bioresearch group driving unique wound care and device modalities through the FDA pipeline in the chronic non-healing wound market. LPP is actively involved in both safety and efficacy studies as well as, pivotal phase III and post market surveillance studies.

Dr. Cazzell was the national investigator and lead author on the largest worldwide randomized control trial utilizing an acellular dermal matrix for chronic non-healing wounds. He is heavily involved in the development of study and protocol design for randomized control trials.